Replimune skin cancer therapy rejected by FDA
Www.statnews.comarrow_outwardFDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection
Stock Titanarrow_outwardFDA rebuffs accelerated approval of Replimune's oncolytic virus, citing lack of supporting data
FirstWord Pharmaarrow_outwardReplimune stock down as FDA rejects cancer drug (REPL:NASDAQ) - Seeking Alpha
Seeking Alphaarrow_outwardRudrabhishek Enterprises Limited (REPL) to Launch New Product Line - Exceptional market positioning - jammulinksnews.com
Jammulinksnews.comarrow_outwardTeacher Retirement System of Texas Has $141,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Defense Worldarrow_outwardWhy Did Replimune Group Stock Soar 9.84% Ahead of FDA Decision? - AInvest
AInvestarrow_outwardREPL Stock Analysis and Forecast - Turbocharged investment results - Autocar Professional
Autocar Professionalarrow_outwardIs REPL a good long term investment - Free Stock Selection - PrintWeekIndia
PrintWeekIndiaarrow_outward(REPL) Investment Analysis and Advice - news.stocktradersdaily.com
News.stocktradersdaily.comarrow_outwardWhy REPL stock attracts strong analyst attention - Proven Win Setups - Newser
Newserarrow_outwardWhen REPL stock expected to show significant growthIs GNRC stock a good long term investment option - Minimized Risk Maximum Return - beatles.ru
Beatles.ruarrow_outwardReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
The Manila Timesarrow_outwardREPL Stock Update: HC Wainwright & Co. Reiterates Buy Rating | REPL Stock News - GuruFocus
GuruFocusarrow_outwardReplimune Group Hosts Investor Day for Updates - TipRanks
TipRanksarrow_outwardJPMorgan reiterates overweight rating on Replimune stock after ASCO - Investing.com
Investing.comarrow_outwardReplimune Group Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing - MarketScreener
MarketScreenerarrow_outward$REPL stock is up 13% today. Here's what we see in our data. - Nasdaq
Nasdaqarrow_outwardReplimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - TradingView
TradingViewarrow_outwardDo Its Financials Have Any Role To Play In Driving Rudrabhishek Enterprises Limited's (NSE:REPL) Stock Up Recently? - simplywall.st
Simplywall.starrow_outwardReplimune stock target raised to $22 at H.C. Wainwright - MSN
MSNarrow_outwardREPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Yahoo Finance
Yahoo Financearrow_outwardReplimune Group, Inc. Announces Proposed Public Offering of $125 Million in Common Stock and Pre-Funded Warrants - Quiver Quantitative
Quiver Quantitativearrow_outwardReplimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat - Stocktwits
Stocktwitsarrow_outwardREPL bags order from TN government - Construction World
Construction Worldarrow_outwardREPL Group gets registration for SM-REIT from Sebi, to launch IPO soon - Business Standard
Business Standardarrow_outwardREPL gets registration for SM-REIT from SEBI; to launch IPO soon - The Economic Times
The Economic Timesarrow_outwardBreakout stocks to buy or sell: Vedanta to Mukta Arts โ Sumeet Bagadia recommends five shares to buy today - Mint
Mintarrow_outwardREPL gets SEBI approval for small and medium REIT, to be named ImpactR SM REIT - Moneycontrol
Moneycontrolarrow_outwardReplimune ignites its stock with phase I/II data in melanoma - BioWorld MedTech
BioWorld MedTecharrow_outwardReplimune Group (REPL) - Zacks Investment Research
Zacks Investment Researcharrow_outward
Repl Stock close
- 2025-07-22 20:10 event
- 31 sourceslanguage
- 200+ ads_click
- 1 month ago schedule